Thursday, October 29, 2020

QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Addresses Continuous Disclosure Review

 Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) has provided an update on its efforts to resolve a continuous disclosure review that was issued earlier this year. Champignon is working closely with the British Columbia Securities Commission (“BCSC”) to coordinate the revocation of the cease trade order and hopes to provide information about a revocation of the order as soon as possible. In the update, the company noted that it has submitted all documentation requested by the BCSC in connection with the review of financial statements of AltMed Capital Corp. (“AltMed”) for the period ended June 30, 2020. The purpose of the review is to ensure compliance with the continuous disclosure obligations outlined by Canadian securities laws. Champignon was notified of the continuous disclosure review on June 19, 2020; the same day, the BCSC issued a cease trade order suspending trading in the securities of SHRM. The trade order requested reports in connection with SHRM’s acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. The requested reports were filed with the BCSC on July 21, 2020, and Champignon has continued to work with the commission to provide documentation and address additional issues that have arisen during the disclosure review process to ensure that the revocation of all orders is issued as soon as possible.

To view the full press release, visit https://ibn.fm/tJT95

About Champignon Brands Inc.

Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury (“mTBI”) with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: